Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Christian B. Schiller"'
Autor:
Todd A. Braciak, Claudia C. Roskopf, Sarah Wildenhain, Nadja C. Fenn, Christian B. Schiller, Ingo A. Schubert, Uwe Jacob, Annemarie Honegger, Christina Krupka, Marion Subklewe, Karsten Spiekermann, Karl-Peter Hopfner, Georg H. Fey, Michael Aigner, Stefan Krause, Andreas Mackensen, Fuat S. Oduncu
Publikováno v:
OncoImmunology, Vol 7, Iss 9 (2018)
A number of agents designed for immunotherapy of Acute Myeloid Leukemia (AML) are in preclinical and early clinical development. Most of them target a single antigen on the surface of AML cells. Here we describe the development and key biological pro
Externí odkaz:
https://doaj.org/article/9c33b3300b544ab9bf536064eecde761
Autor:
Birgit Bossenmaier, Gerhard Niederfellner, Karl-Peter Hopfner, Irene Kolm, Gabriele Hoelzlwimmer, Valeria Lifke, Ulrike Reiff, Christian A. Gerdes, Thomas Friess, Nikolaos Dimoudis, Michael Schräml, Christian B. Schiller, Christian Mirschberger
PDF file - 470K, Calculation of tumor growth inhibition. Tumor growth inhibition was calculated compared with respective controls using a standard formula. Surface plasmon resonance. Calculation of kinetic parameters ka (1/Ms), kd (1/s) and KD (M) of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3feaa2dd38c3bfb8639bb45849ca3ac9
https://doi.org/10.1158/0008-5472.22400820.v1
https://doi.org/10.1158/0008-5472.22400820.v1
Publikováno v:
Immunobiology. 223:699-708
The LST1 gene is located in the MHC class III cluster between the MHC class I and II regions. While most genes in this cluster have been sufficiently characterised, a definitive function and expression pattern for LST1 still remains elusive. In the p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b45c9ce7c1bb222a0688362979bbdc4
https://doi.org/10.1016/j.imbio.2018.07.018
https://doi.org/10.1016/j.imbio.2018.07.018
Autor:
Ingo Schubert, Christina Krupka, Andreas Mackensen, Karsten Spiekermann, Annemarie Honegger, Sarah Wildenhain, Todd A. Braciak, Stefan W. Krause, Marion Subklewe, Nadja C. Fenn, Uwe Jacob, Christian B. Schiller, Georg H. Fey, Michael Aigner, Claudia C. Roskopf, Fuat Oduncu, Karl-Peter Hopfner
Publikováno v:
OncoImmunology, Vol 7, Iss 9 (2018)
Oncoimmunology
Oncoimmunology
A number of agents designed for immunotherapy of Acute Myeloid Leukemia (AML) are in preclinical and early clinical development. Most of them target a single antigen on the surface of AML cells. Here we describe the development and key biological pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08f15f5ec16fb9f8d9620efd3e57b652
https://doaj.org/article/9c33b3300b544ab9bf536064eecde761
https://doaj.org/article/9c33b3300b544ab9bf536064eecde761
Autor:
Todd A. Braciak, Sebastian Kobold, Fuat Oduncu, Karl-Peter Hopfner, Georg H. Fey, Christian B. Schiller, Claudia C. Roskopf, Ingo Schubert
Publikováno v:
Oncotarget
ResearcherID
ResearcherID
Triplebody 19-3-19, an antibody-derived protein, carries three single chain fragment variable domains in tandem in a single polypeptide chain. 19-3-19 binds CD19-bearing lymphoid cells via its two distal domains and primary T cells via its CD3-target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c13efc4aaf1957fda0ce2af7775f1e8b
https://doi.org/10.18632/oncotarget.2238
https://doi.org/10.18632/oncotarget.2238
Autor:
Karl-Peter Hopfner, Alexandra Schele, Ursula J.E. Seidel, Nadja C. Fenn, Annemarie Honegger, Christian B. Schiller, Todd A. Braciak, Sarah Wildenhain, Fuat Oduncu, Ingo Schubert, Kerstin Lämmermann, Peter Lang, Georg H. Fey, Claudia C. Roskopf, Uwe Jacob
Publikováno v:
Oncotarget
// Christian B. Schiller 1, * , Todd A. Braciak 2, * , Nadja C. Fenn 1, * , Ursula J. E. Seidel 3, * , Claudia C. Roskopf 2, * , Sarah Wildenhain 1, * , Annemarie Honegger * , Ingo A. Schubert 5 , Alexandra Schele 1 , Kerstin Lammermann 2 , Georg H.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f9594975ab5fee990d155d3a61be0db
https://pubmed.ncbi.nlm.nih.gov/27825135
https://pubmed.ncbi.nlm.nih.gov/27825135
Publikováno v:
Cold Spring Harbor Perspectives in Biology
DNA double-strand breaks are repaired by two major pathways, homologous recombination or nonhomologous end joining. The commitment to one or the other pathway proceeds via different steps of resection of the DNA ends, which is controlled and executed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f481815277649f228acb021c82d11296
https://pubmed.ncbi.nlm.nih.gov/25081516
https://pubmed.ncbi.nlm.nih.gov/25081516
Autor:
Christian B. Schiller, Carina Nowak, Elisabeth H. Weiss, Ulrich H. Weidle, Kalliope N. Diakopoulos
Publikováno v:
PLoS ONE
PLoS ONE, Vol 9, Iss 5, p e96245 (2014)
PLoS ONE, Vol 9, Iss 5, p e96245 (2014)
The regulation of gene expression depends on the interplay of multiple factors at the transcriptional and translational level. Upstream open reading frames (uORFs) play an important role as translational repressors of main ORFs and their presence or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aebbc122351fb9bfc6f23a4f27633792
http://europepmc.org/articles/PMC4015914
http://europepmc.org/articles/PMC4015914
Autor:
Karl-Peter Hopfner, Nadja C. Fenn, Sarah Wildenhain, Christian B. Schiller, Uwe Jacob, Fuat Oduncu, Claudia C. Roskopf, Todd A. Braciak, Georg H. Fey
Publikováno v:
Journal for Immunotherapy of Cancer
Meeting abstracts The design of antibody derivatives with higher tumour cell selectivity is hoped to improve cancer immunotherapy and to decrease side effects. One promising molecular format that we have developed is the triple body. A triple body al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1b2e7e8f0b8dd19886994d380411974
https://doi.org/10.1186/2051-1426-2-s2-p19
https://doi.org/10.1186/2051-1426-2-s2-p19
Autor:
Christian Gassner, Christian Klein, Joerg Thomas Regula, Julia J. Griese, Sabine Imhof-Jung, Wolfgang Schaefer, Joerg Moelleken, Karl-Peter Hopfner, Hubert Kettenberger, Christian B. Schiller, Sebastian Fenn, Harald Duerr, Markus Thomas
Publikováno v:
PLoS ONE
PLoS ONE, Vol 8, Iss 4, p e61953 (2013)
PLoS ONE, Vol 8, Iss 4, p e61953 (2013)
Bispecific antibodies are considered as a promising class of future biotherapeutic molecules. They comprise binding specificities for two different antigens, which may provide additive or synergistic modes of action. There is a wide variety of design
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45f4bf31fc68fdd1823d6be93a581f42
https://pubmed.ncbi.nlm.nih.gov/23613981
https://pubmed.ncbi.nlm.nih.gov/23613981